Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study

View Full Paper
Ask AI
Bookmark
Share

Authors

KDKeyur DesaiCBChad C. BjorklundJHJoseph T. Hadala

Discussion

Loading...

Member takes

Overview

Phase 1/2 trial shows mezigdomide combined with dexamethasone improves progression-free survival in relapsed/refractory multiple myeloma patients.

Key Points

  • This research aims to evaluate the pharmacodynamic activities and clinical benefits of mezigdomide in high-risk molecular subgroups of multiple myeloma.
  • Analyzed blood and bone marrow samples for biomarkers in patients with relapsed/refractory multiple myeloma receiving mezigdomide and dexamethasone.
  • Measured pharmacodynamic biomarkers including Aiolos expression in T cells and serum free light chain levels.
  • Conducted whole-genome sequencing to identify high-risk molecular features.
  • Mezigdomide demonstrated pharmacodynamic activity in patients previously treated with pomalidomide.
  • Aiolos and light chain degradation correlated with improved progression-free survival measures in patients with high-risk features.
  • Biomarker analysis showed significant associations with clinical outcomes and tumor burden reduction.

Cite This Study

Desai et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3fahttps://doi.org/10.1182/blood-2025-5697
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial2023 · 13 citations
  2. 2Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 12025 · 2 citations
  3. 3Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM).2024 · 1 citations
  4. 4Real-world efficacy and safety of mezigdomide-dexamethasone in heavily pre-treatred multiple myeloma patients: An Italian case series2025 · 2 citations
  5. 5EZH2 inhibition synergizes with aiolos/ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma2025 · 2 citations